Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study of spiroplatin.

B C Tanis1, J B Vermorken, W W ten Bokkel Huinink

  • 1Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
PubMed
Summary

This phase I study found that spiroplatin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024
Same author

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2017
Same author

Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy.

Breast (Edinburgh, Scotland)·2013
Same author

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.

Sarcoma·2007

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Spiroplatin is a novel platinum-based chemotherapy agent.
  • Platinum compounds are widely used in cancer treatment.
  • Understanding spiroplatin's toxicity and efficacy is crucial for its clinical application.

Purpose of the Study:

  • To determine the maximum tolerated dose (MTD) of spiroplatin.
  • To evaluate the safety and tolerability profile of spiroplatin.
  • To identify a recommended dose for phase II trials.

Main Methods:

  • A multicenter phase I clinical trial.
  • 67 patients with advanced solid tumors received spiroplatin.
  • Doses ranged from 2.5-40 mg/m2 via short-term or prolonged infusion every 3 weeks.

Main Results:

  • Dose-limiting toxicities included myelosuppression and renal toxicity.
  • Proteinuria indicated glomerular and tubular damage, dependent on dose and schedule.
  • MTD was 35 mg/m2 for poor-risk and 40 mg/m2 for good-risk patients.

Conclusions:

  • The recommended dose for phase II studies is 30 mg/m2 administered over 4 hours every 3 weeks.
  • Spiroplatin exhibits dose- and schedule-dependent renal toxicity.
  • Further investigation is warranted to optimize spiroplatin's therapeutic index.

Related Experiment Videos